Skyhawk signs neuro deal with Takeda as it prepares to expand its partnered indications

Skyhawk signed its third major deal in a year, this time with Takeda. Like its first two partnerships, the focus will be in neurology, but Skyhawk is in discussions with companies that could help extend its platform to other areas.

On Tuesday, Skyhawk Therapeutics Inc. (Waltham, Mass.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive worldwide rights to therapies against multiple targets for undisclosed neurodegenerative diseases. Skyhawk will be responsible for discovery and preclinical development using its SkySTAR platform, after which Takeda will take over the programs. Financial details are undisclosed...